Many physicians regard doxorubicin hydrochloride (dox) as an important part of therapy. CALGB(US) for example, have entered more than 1,500 patients into a trial comparing three different doses of CAF (Henderson, 1991) . The value of dox in advanced breast cancer is the subject of debate which centres on the trade off between toxicity and efficacy. Belanger et al. (1991) 
Statistical methods
Response rates were combined using the Mantel-Haenszel method, (Mantel et al., 1959) and the method described below was used to combine log hazard ratios. Both these methods do not allow differences between trials to contribute to the standard error of the overall estimate of the treatment effect. An alternative approach is to use techniques in which it is assumed that each study has a true effect which it estimates, the combined effect across studies is then based on the estimates of the true effect for each study (Berlin, 1989) . The trials are thus considered to be a random sample of all possible trials which address the comparison of interest. Reviews of the type undertaken in this paper are best construed as giving qualitative rather than quantitative results (Thompson & Pocock, 1991) .
The method of comparing time to treatment failure and survival curves was based on estimation of the hazard ratio and its variance from the published curves and the P-value for their comparison. A worked example is given in Appendix I. The hazard ratio and its variance were not given directly in any of the published papers. These hazard ratios were then combined across studies if a test for heterogeneity between studies was non-significant. Curves representing time to treatment failure were combined whether or not they included death as an endpoint, in some cases this was not explicitly stated.
If the proportional hazards model is assumed to apply then the hazard ratio (HR) can be estimated from F1(t) = (F2(t))HR. Thus HR = ln(Fj(t))/ln(F2(t)) where FI(t) and F2(t) are the values of the survivor functions in the two arms being compared at time t. The hazard ratio for each trial was estimated over each 6 month period and a weighted average (of the log hazard ratio) taken where the weighting factor for each period was the estimated number of deaths. The number of deaths can be used as a weighting factor because the variance of the log hazard ratio will be approximately inversely proportional to the number of events. If, for example, there was no censoring and the event rate followed an exponential distribution, the log hazard ratio would have a variance estimated by (d1 + d2)/dld2 where dI and d2 are the number of events in the groups being compared (Kalbfleisch & Prentice, 1980) . Assuming there are approximately the same number of events (d) in each group the variance then becomes 2/d. The reciprocal of this is then half the number of events and the number of events can therefore be used as a weighting factor. The number of events has been calculated from the original number at risk and the change in the proportion event free within each interval.
For simplicity, it was assumed there was no censoring, thus slightly too much weight will have been attached to the hazard ratios estimated from the right of the curves. Appendix I includes a recalculation of the example assuming 5% censoring in each interval. After tests for heterogeneity had been performed (Armitage & Berry, 1990 ), log hazard ratios were then combined across trials using an inverse variance weighting.
Where P-values were not given exactly the highest estimate was used e.g. P<0.01 was taken as P = 0.01. In some instances Gehan's test had been used to compare curves, the P-value from this test was employed although it may not always be the same as that derived under the proportional hazards assumption. In order to summarise the data the average per cent failure free, response rates and per cent surviving were calculated as weighted averages from the individual trials.
Results
No relevant differences in patient characteristics between studies were noted. The results for individual trials are shown graphically in Figure 1 The largest randomised clinical trial (known to the authors) addressing the value of the inclusion of dox compares CAF and CMF (Madsen et al., 1991) (Freedman, 1989) can be considered. The recognition that a trial which a group wishes to undertake will not yield a worthwhile evaluation of the treatments being assessed can be an obstacle to research. If other groups are undertaking trials addressing a similar question, however, the outcomes from such parallel studies can be combined using overview methodologies, and this will increase the probability 30 36 of a meaningful conclusion. This paper emphasises the value of parallel studies in advanced cancer. It also reinforces the start need for information based on treatment as allocated to be published on the endpoints of response rate, response duraring overall failure tion, time to disease progression and survival. These endtage from the indipoints could be mandatory before a trial was to be considered for publication. In addition, ethics committees could demand that trials are registered with cancer trials registries so that they will be traceable by groups wishing to perform (2) A(7)=a (7) 1.0 a(l) A(6) CMFVP (A(7) ) ...
In(B(I))
In(B (7) The P-value for the comparison of the curves is P = 0.01 (from the published paper) this corresponds to a 2-sided standardised normal deviate of 2.58 (z) The standard error of LH (which is always positive) is then approximately LH=0.176 (s) and its variance is 0.031 (s2) z (ii) Combining several log hazard ratios. Suppose the above trial was the first was the first trial in a series contributing to an overview and let the log hazard ratio calculated above be LHR(J) and its variance V(J), a third quantity W(l), the inverse variance weighting factor can be calculated.
If Heterogeneity between trials can be tested by calculating G = 4.91 G = GJ-G22/TW which has a Chi-square distribution with 4 (Number of trials-l) degrees of freedom (P = 0.30). If this reaches statistical significance then there is evidence that the treatment effect differs between trials, so calculation of a common overall treatment effect is not justified. The hypothesis that OLHR is zero, i.e. that there is no treatment effect, can be tested by calculating the Chi-square statistic OLHR2*TW (11.0 in this case) which is compared against a Chi square distribution with one degree of freedom.
(iii) Allowing for censoring.
The assumption made above that there is no censoring will result in greater weight being given to the hazard ratios calculated from the tail of the curve than would occur in practice. Censoring might be allowed for by assuming that a constant proportion C are censored in each interval. This will add in an extra term to the calculation of the number of deaths in each interval, D(i) = (l-C)' * [NJ*(a(i-l)-a(i)) + N2*(b(i-1)-b(i)) ] where i is the interval number.
Assuming that there is 5% censoring in each interval above, the hazard ratio becomes 0.79 (95% CI: 0.68-0.90), there is thus little change.
